0001209191-19-050922.txt : 20190926
0001209191-19-050922.hdr.sgml : 20190926
20190926211727
ACCESSION NUMBER: 0001209191-19-050922
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190924
FILED AS OF DATE: 20190926
DATE AS OF CHANGE: 20190926
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Levine James E.
CENTRAL INDEX KEY: 0001463151
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36912
FILM NUMBER: 191119443
MAIL ADDRESS:
STREET 1: 55 CAMBRIDGE PARKWAY
STREET 2: 8TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cidara Therapeutics, Inc.
CENTRAL INDEX KEY: 0001610618
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 461537286
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6310 NANCY RIDGE DRIVE
STREET 2: SUITE 101
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-752-6170
MAIL ADDRESS:
STREET 1: 6310 NANCY RIDGE DRIVE
STREET 2: SUITE 101
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: K2 THERAPEUTICS, INC.
DATE OF NAME CHANGE: 20140611
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-09-24
0
0001610618
Cidara Therapeutics, Inc.
CDTX
0001463151
Levine James E.
C/O CIDARA THERAPEUTICS, INC.
6310 NANCY RIDGE DR #101
SAN DIEGO
CA
92121
0
1
0
0
Chief Financial Officer
Common Stock
2019-09-24
4
P
0
30000
1.908
A
205000
D
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.90
to $1.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and
Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set
forth above.
/s/ Jessica Oien, Attorney-in-fact
2019-09-26